The CFO's statement on share repurchases being the lowest priority could signal a neutral to slightly negative sentiment among investors who favor buybacks as a method of returning value. However, it could also indicate that Pfizer is investing in growth or other strategic initiatives, which might be viewed positively in the long term. The short-term impact is likely to be neutral as the market digests the implications of this strategy.